Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EIF4A3 | P38919 | 7/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699546 | 0.87 | MDM2 (0.43) | HPGDMDM2LMNAPOLBMAPT | |
| SCHEMBL13699657 | 0.85 | MDM2 (0.44) | HPGDMDM2LMNAPOLBEIF4A3 | |
| SCHEMBL13699605 | 0.82 | CXCR4 (0.42) | MDM2POLBKMT2AMEN1RIPK1 | |
| SCHEMBL4160818 | 0.82 | RIPK1 (0.44) | MDM2EIF4A3KMT2AMEN1RIPK1 | |
| SCHEMBL4160826 | 0.82 | RIPK1 (0.44) | MDM2EIF4A3KMT2AMEN1RIPK1 | |
| SCHEMBL13699600 | 0.81 | MDM2 (0.39) | HPGDMDM2RIPK1 | |
| SCHEMBL13699576 | 0.80 | RIPK1 (0.39) | MDM2LMNAMAPTKMT2AMEN1 | |
| SCHEMBL13699577 | 0.80 | RIPK1 (0.39) | MDM2LMNAMAPTKMT2AMEN1 | |
| SCHEMBL13699575 | 0.80 | RIPK1 (0.41) | MDM2LMNAMAPTKMT2AMEN1 | |
| SCHEMBL13699554 | 0.79 | AKR1C3 (0.49) | HPGDMDM2LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| WO-2007057687-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY | VERNALIS (R & D) LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | HPGD 2209/4885MDM2 2997/4885LMNA 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.